lenvatinib

This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).

Latest news

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

rights for Lenvima (lenvatinib) and start a series of clinical trials in combination with Keytruda (pembrolizumab).
NICE reverses its rejection of Eisai’s Lenvima

The cost-effectiveness watchdog has now backed the thyroid cancer treatment. The National Institute for Health and Care Excellence (NICE) has recommended the use of Lenvima (lenvatinib) after manufacturer Eisai was ... that NICE is finally recommending
NICE gives green light to Ipsen's Cabometyx

Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s
NICE backs Eisai's Halaven for breast cancer

The company "would like the same opportunity to enable access to our newer cancer drug lenvatinib for radioiodine refractory differentiated thyroid cancer patients, however so far an unacceptable process has again
Eisai wins EU licence for kidney cancer drug Kisplyx

Approved as a second-line combination treatment for advanced RCC. The European Commission has approved Kisplyx (lenvatinib) for the treatment of adults with advanced renal cell carcinoma (RCC) after an accelerated ... We remain committed to exploring the

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Digital Account Director: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Medical Writer: Great salary and benefits

Project Manager/ Account Manager: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Subscribe to our email news alerts

PMHub

Add my company

HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age: Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge: Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis: Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....